<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01188148</url>
  </required_header>
  <id_info>
    <org_study_id>BPMM HR-98-025</org_study_id>
    <nct_id>NCT01188148</nct_id>
  </id_info>
  <brief_title>Series Studies of Bipolar Disorder-Valproate add-on Memantine</brief_title>
  <acronym>MM</acronym>
  <official_title>Series Studies of Bipolar Disorder-Valproate add-on Memantine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cheng-Kung University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cheng-Kung University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All participants should fulfill the following criteria: aged between 18 and 65 years old, and
      of domestic Han descendants. Participants will be randomly assigned to either the (1)
      pharmacotherapy (valproate add-on memantine) group; (2) pharmacotherapy (valproate add-on
      memantine) plus Cognitive Behavior Group Therapy (CBGT) group; (3) valproate add-on placebo
      plus CBGT group, or (4) valproate add-on placebo only group. A total of 240-320 individuals
      (60-80 participants per group) will be recruited for this study. For each CBGT group,
      12-weekly sessions are scheduled according to patients' preference. The investigators will
      attempt to understand the effects of pharmaceutical drugs for mood stabilizers add-on
      neuro-protective drugs, pharmacotherapy with CBGT, mood stabilizer with CBGT, and the use of
      only traditional mood stabilizers in the treatment of BP II. Comparisons will be made for
      each type of treatment and possible mechanisms will be examined regarding the pharmacotherapy
      and CBGT for bipolar disorder patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Young's Mania Rating Scale (YMRS)</measure>
    <time_frame>baseline, 1, 2, 4, 8 and 12 weeks</time_frame>
    <description>Normally, YMRS is used to evaluate the Bipolar Disorder Patient's mood change.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HDRS)</measure>
    <time_frame>baseline, 1, 2, 4, 8 and 12 weeks</time_frame>
    <description>Normally, YMRS is used to evaluate the Bipolar Disorder Patient's mood change of depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cytokines</measure>
    <time_frame>baseline, 1, 2, 4, 8 and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>baseline, 1, 2, 4, 8 and the week 12</time_frame>
    <description>CGI will be used to evaluate how the patient's adverse effect go on during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipid profiles</measure>
    <time_frame>baseline, 1, 2, 4, 8 and 12 weeks</time_frame>
    <description>HDL, LDL, cholesterol and etc.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>genetics</measure>
    <time_frame>baseline</time_frame>
    <description>ALDH2, ADH1B, COMT, DRD2, DRD3, BDNFVal66Met</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Bipolar Disorders</condition>
  <arm_group>
    <arm_group_label>VPA &amp; Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VPA &amp; Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VPA &amp; memantine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Memantine</intervention_name>
    <description>5 mg per day of memantine</description>
    <arm_group_label>VPA &amp; memantine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>VPA &amp; Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient aged &gt;=18 and &lt;= 65 years.

          2. A diagnosis of bipolar II disorder according to DSM-IV-TR criteria made by a
             specialist in psychiatry.

          3. A total of HDRS score at least 18 or YMRS score at least 14 at screen.

          4. Signed informed consent by patient or legal representative.

        Exclusion Criteria:

          1. Women of childbearing potential not using adequate contraception as per investigator
             judgment or not willing to comply with contraception for duration of study.

          2. Females who are pregnant or nursing.

          3. Patient has received memantine or other selective cyclo-oxygenase 2 (Cox-2) inhibitors
             within 1 week prior to first dose of double-blind medication.

          4. Axis-I DSM-IV-TR diagnosis other than bipolar II disorder.

          5. Current evidence of an uncontrolled and/or clinically significant medical condition
             (e.g., cardiac, hepatic and renal failure), which in the judgments of the
             investigator, would compromise patient safety or preclude study participation.

          6. History of intolerance to valproate or memantine or other Cox-2 inhibitors.

          7. History of sensitivity reaction (e.g., urticaria, angioedema, bronchospasm, severe
             rhinitis, anaphylactic shock) precipitated by memantine

          8. Patient has received electroconvulsive therapy (ECT) within 4 weeks prior to first
             dose of doubleblind medication.

          9. Inclusion in another bipolar disorder study or study for another indication with
             psychotropic's within the last 30 days prior to start of study.

         10. Increase in total SGOT, SGPT, BUN and creatinine by more than 3X ULN (upper limit of
             normal).

         11. Substance-related disorders within 6 months prior to study start, borderline
             personality disorder, schizophrenia, or other major psychiatric disorders as defined
             by DSM-IV criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ru-Band Lu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cheng-Kung University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ru-Band Lu</name>
      <address>
        <city>Tainan</city>
        <zip>704</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2010</study_first_submitted>
  <study_first_submitted_qc>August 23, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2010</study_first_posted>
  <last_update_submitted>September 16, 2013</last_update_submitted>
  <last_update_submitted_qc>September 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Memantine</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

